logo
How Can We Live Longer?

How Can We Live Longer?

Bloomberg6 days ago
Live on Bloomberg TV
CC-Transcript
00:00We spend so much time talking about this and I wonder what's making you invest in it now? Why are we all so consumed with our own mortality? Well, as people all get older, they generally want to live longer. Most people do. I think it's all it's been going on for a millennium. But now we have the ability with medications and pharmaceutical products and lifestyle changes to actually affect how long we live. So in the year, let's say 400,000 years ago, when humans were coming out of caves as Homo sapiens, the life expectancy was 20. Today, in the United States, the life expectancy is roughly 77. But somebody born today from a good zip code, good ethnicity can probably live to 85 to 90. But people today who are already in their 56 years and seventies, what they want to do is live longer. And it's possible now because of drugs, more knowledge about weight, more knowledge about pharmaceuticals, more knowledge about so many different lifestyle changes that one could adopt that you can live longer. And so this series is about how people can affect the time that they spend on the face of the earth. So that's what it's all about. We selected that clip on GLP one, which has been such a fascinating story over the past couple of years. David A cure all. If you ask certain people, everything from fatty liver to diabetes to obesity to sleep apnea. Have we ever seen something like this that's been approved for so many things? And to what extent does this advance our conversation about advancing our age? Well, we all remember when school that penicillin was discovered as an accident and we later learned that penicillin turned out to be one of the great miracle drugs of all time and saved many, many lives, of course, around the world and still does. GLP one drugs were originally designed to deal with diabetes and the effects of diabetes. But it turns out that they have more significant effects in just dealing with diabetes. They can also make you lose a fair amount of weight, you know, in a way that's responsible. But also they can probably extend your life. And now more and more research is being done to see that the show that GLP one drugs can probably save you many, many years on the face of the earth. You can live longer. And so many, many doctors are now beginning to prescribe it not just for obesity but for other related things that people can can deal with. You're no stranger to politics, of course, David Rubenstein. And I'm wondering if it's possible in this political climate we're in to talk about health in an era when Donald Trump is talking about Marjo and RFK jr is questioning certain sciences. If it's possible to talk about our health without bumping into politics. Well, in Washington, D.C., everything revolves around politics to some extent. But yeah, generally the most important thing I think we should recognize is that the purpose of government is to promote the general welfare. That's what it says in our Constitution and what promotes the general welfare better than helping people to live longer and living healthier. And that's what health is all about. We have the finest medications in the United States, the finest health care in the United States. We just to make sure that people are get access to it. And that's what the debate often is about in Washington. Who's going to get access to the health care and how much are they going to pay for it? But what I'm trying to do with this series is just make be sure people realize that it is possible through changing your lifestyle. They're taking some medications you can live longer than you otherwise would live. And that's something that generally people all over the world want to do more than anything else. People want to have a happy life, a healthy life and a longer life. Yeah, well, it's pretty remarkable how simple that is. And you wonder what happens to GLP one's what else they could be approved for if there's an oral version or so forth. But, David, there's a lot of debate in Washington right now about a number of things, including pharmaceuticals, including whether they should be tariffs. As I said at the beginning of our conversation here, and I have to ask you about the way the market is looking at all of this, because you're David Rubenstein, when you see the markets continuing to see new highs in the face of such uncertainty as we've been told. What do you make of this moment, the psychology in the markets, knowing that August 1st is less than two weeks away? Is this market more sophisticated, a better sense of what's real and what's noise than the political class in Washington? Well, the market generally is a pretty good indicator what people are thinking. As a general rule of thumb. I think most CEOs and most large companies today do not know what the impact of tariffs is going to be going to be. And so it really hasn't factored in that much yet. Most companies, many of the companies that my own firm has under our control don't yet see the need to raise prices to deal with the tariffs because the tariffs aren't yet solidified in terms of what they're going to be. But I think most people in the market generally think that tariffs will be tolerable and probably some price is going to be passed along and maybe some others can't. But I don't think most people feel that the tariffs are now a barrier to continued economic growth. That's fascinating. How about the idea of Donald Trump as chairman of the board, having seen him make moves on specific companies? We'll take a look at what he said about Tim Cook, for instance, at Apple. It's time to move your manufacturing here, and I need you to do it by this date. David is the co-founder of Carlisle. How should board members or people in the C-suite prepare for that type of environment? Well, there is a manufacturing deficit now in the United States. There's no doubt that manufacturing has moved offshore over the last 20 to 30 years because it's very efficient to manufacture things at lower prices offshore. There's no doubt that many CEOs are now beginning to onshore some manufacturing. But we have to be realistic about it. It takes many, many years to build the manufacturing facilities, the United States. So it may be some time before much manufacture is going to come back here. But I suspect some companies are going to manufacture some things in the United States they otherwise would not. But some are going to give lip service to it and some are not really going to pay that much attention to it. In the end, I suspect there will be more manufacturing in the United States three or four years from now than there is today, but a lot less than there was 20 or 30 years ago.
For YouLive TV
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Colipse Coffee Expands Its Swiss Water® Decaf Line with New Sizes and Grind Options
Colipse Coffee Expands Its Swiss Water® Decaf Line with New Sizes and Grind Options

Associated Press

time2 hours ago

  • Associated Press

Colipse Coffee Expands Its Swiss Water® Decaf Line with New Sizes and Grind Options

Chemical-free decaf gets major upgrade with four bag sizes, precision grinds, and bulk savings up to 40% per ounce 'Decaf is no longer just a side option. Our customers want the same richness and complexity they get from regular coffee so we revisited the roast and built a lineup that stands on its own.'— Michal Sieroslawski, founder of Colipse Coffee BOSTON, MA, UNITED STATES, July 27, 2025 / / -- Colipse Coffee, a specialty coffee brand that has seen 200% growth in decaf coffee sales over the past year, today announced a comprehensive expansion of its Swiss Water® Process decaf collection. The upgrade introduces four bag sizes, four grind options, and bulk pricing that saves customers up to 40% per ounce. The decaf market is growing steadily as consumers increasingly prioritize sleep quality, anxiety management, and caffeine control for medical conditions. Pregnant women, medication users, and those with digestive sensitivities are driving demand for high-quality decaf that doesn't sacrifice taste. Unlike traditional chemical methods using methylene chloride or ethyl acetate, Colipse's Swiss Water® process removes 99.9% of caffeine using only water, temperature, and time – making it increasingly valuable to health-conscious consumers. The numbers reflect this shift: the global decaffeinated coffee market reached $2.39 billion in 2024 and is projected to grow at 7.2% annually through 2035, significantly outpacing traditional coffee. The National Coffee Association reports 7% of Americans now consume decaf daily, with strongest growth among health-focused consumers aged 40 and over. Product Expansion Details Bag Sizes: Now offered in 12 oz, 16 oz, 2 lb, and 5 lb formats for all Colipse Swiss Water decaf coffees Grind Options: Available as whole bean, coarse (for French press & cold brew), medium (for drip), and fine (for espresso & moka) Bulk Savings: Customers can save up to 40% per ounce with larger 5 lb bags Flexible Subscriptions: Choose grind type, bag size, delivery schedule, and pause or skip anytime The expanded line works seamlessly with popular equipment including Jura, De'Longhi, Breville, and Gaggia machines, plus manual methods like Chemex, Hario V60, and French press. Each order is roasted fresh, vacuum-sealed for peak flavor retention, and ships free across the United States. The expanded Swiss Water® decaf line is available immediately at with introductory pricing starting at $21.95 for 12 oz bags. Bulk discounts apply automatically, and subscription customers receive an additional 5% off all orders. 'I was looking for the cleanest and best decaf coffee on the market and I think I found it,' said Charlotte Anderson, a Colipse customer. 'This coffee is delicious - my stomach can't handle caffeine, but I don't have to sacrifice taste.' About Colipse Coffee Founded in 2024, Colipse Coffee is a New Mexico-based specialty coffee company committed to delivering exceptional coffee through sustainable practices and innovative processing methods. The company has experienced rapid growth by focusing on quality, freshness, and customer service. Michal Sieroslawski Colipse Coffee +1 505-445-3781 email us here Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Northern Lights Could Be Visible From These 8 States Sunday Night
Northern Lights Could Be Visible From These 8 States Sunday Night

Forbes

time5 hours ago

  • Forbes

Northern Lights Could Be Visible From These 8 States Sunday Night

The northern lights have a moderate chance to appear for viewers in the northern United States on Sunday night, the National Oceanic and Atmospheric Administration predicted, coinciding with meteor showers potentially visible in the summer night skies. The aurora visible over Fairbanks, Alaska in March. Anadolu via Getty Images Forecasters at NOAA issued a Kp index of three out of nine for Sunday night, meaning the aurora could become 'brighter' with 'more auroral activity (motion and formations).' The aurora was likely much more active Saturday night due to the presence of a geomagnetic storm, NOAA said, but several states in the Upper Midwest and Alaska could still see auroral activity on Sunday night. Meanwhile, the Piscis Austrinid meteor shower is expected to peak in the early morning hours of Monday morning. NOAA's viewing line for Sunday night. NOAA Much of the Upper Midwest is within Sunday night's viewing range, including North Dakota, parts of Montana, northern Minnesota and Wisconsin, and Michigan's Upper Peninsula. Alaska has the potential for northern lights Sunday, as well. Small slivers of northeastern Washington and northern Idaho are also within the viewing range, according to NOAA. Between 10 p.m. and 2 a.m., according to NOAA. The aurora is brightest and most active during the hours around midnight, according to forecasters. Viewers hoping to catch a glimpse of the northern lights should try to move toward the magnetic north pole and away from cities and other sources of light pollution. What Else Could I See Tonight? The aurora borealis coincides with several major meteor showers actively taking place in the summer skies, including the annual Perseid meteor shower that began on July 17, although that shower is not expected to peak until August. Stargazers could also catch a glimpse of the Piscis Austrinid meteor shower, which will peak overnight, or the Southern Delta Aquariids, which will peak Tuesday.

Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup

Yahoo

time8 hours ago

  • Yahoo

Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup

Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) has faced stock pressure due to its reliance on Keytruda but is diversifying. On July 9, Merck announced it would acquire UK biotech Verona Pharma for $10 billion, adding Ohtuvayre, a promising COPD treatment approved last year, to its portfolio. Ohtuvayre has had a strong launch and is being studied for more uses. Some analysts predict its sales could reach $4 billion, potentially making it another blockbuster for Merck. In its first quarter earnings, Merck & Co., Inc. (NYSE:MRK) highlighted that it began the year with strong progress, driven by growing contributions from its recently commercialized medicines and vaccines, along with ongoing advancements in its pipeline. It is focused and determined to fully capitalize on near-term opportunities while swiftly advancing the next wave of innovations that will improve patient outcomes and create long-term value for all stakeholders. Merck & Co., Inc. (NYSE:MRK) is also popular because of its dividend growth history, which spans 16 consecutive years. Currently, the company offers a quarterly dividend of $0.81 per share and has a dividend yield of 3.82%, as of July 26. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store